FDA Prioritizes Review of Fenebrutinib for Multiple Sclerosis Treatment

The FDA has accepted a New Drug Application for fenebrutinib, a potential treatment for relapsing and primary progressive multiple sclerosis, under priority review. This oral Bruton tyrosine kinase inhibitor could be the first oral therapy approved for primary progressive MS if successful. The application is backed by data from three Phase 3 trials, highlighting its significance in MS treatment options.